These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35470769)

  • 1.
    Chavda VP; Pandya A; Kypreos E; Patravale V; Apostolopoulos V
    Expert Rev Vaccines; 2022 Jun; 21(6):771-781. PubMed ID: 35470769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intramuscular Immunisation with Chlamydial Proteins Induces Chlamydia trachomatis Specific Ocular Antibodies.
    Badamchi-Zadeh A; McKay PF; Holland MJ; Paes W; Brzozowski A; Lacey C; Follmann F; Tregoning JS; Shattock RJ
    PLoS One; 2015; 10(10):e0141209. PubMed ID: 26501198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of Chlamydia trachomatis infection and the requirements for a vaccine.
    Schachter J
    Rev Infect Dis; 1985; 7(6):713-6. PubMed ID: 3840910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ophthalmia neonatorum in a trachoma endemic area.
    Datta P; Frost E; Peeling R; Masinde S; Deslandes S; Echelu C; Wamola I; Brunham RC
    Sex Transm Dis; 1994; 21(1):1-4. PubMed ID: 8140482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Status of vaccine research and development of vaccines for Chlamydia trachomatis infection.
    Poston TB; Gottlieb SL; Darville T
    Vaccine; 2019 Nov; 37(50):7289-7294. PubMed ID: 28111145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple Chlamydiaceae species in trachoma: implications for disease pathogenesis and control.
    Dean D; Kandel RP; Adhikari HK; Hessel T
    PLoS Med; 2008 Jan; 5(1):e14. PubMed ID: 18177205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conjunctival FOXP3 expression in trachoma: do regulatory T cells have a role in human ocular Chlamydia trachomatis infection?
    Faal N; Bailey RL; Jeffries D; Joof H; Sarr I; Laye M; Mabey DC; Holland MJ
    PLoS Med; 2006 Aug; 3(8):e266. PubMed ID: 16881731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chlamydial eye infections: Current perspectives.
    Satpathy G; Behera HS; Ahmed NH
    Indian J Ophthalmol; 2017 Feb; 65(2):97-102. PubMed ID: 28345563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards a safe and effective chlamydial vaccine: lessons from the eye.
    Mabey DC; Hu V; Bailey RL; Burton MJ; Holland MJ
    Vaccine; 2014 Mar; 32(14):1572-8. PubMed ID: 24606636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on Chlamydia trachomatis Vaccinology.
    de la Maza LM; Zhong G; Brunham RC
    Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28228394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection.
    Whittum-Hudson JA; An LL; Saltzman WM; Prendergast RA; MacDonald AB
    Nat Med; 1996 Oct; 2(10):1116-21. PubMed ID: 8837610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendrimer-conjugated peptide vaccine enhances clearance of Chlamydia trachomatis genital infection.
    Ganda IS; Zhong Q; Hali M; Albuquerque RLC; Padilha FF; da Rocha SRP; Whittum-Hudson JA
    Int J Pharm; 2017 Jul; 527(1-2):79-91. PubMed ID: 28546072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Chlamydia trachomatis vaccine for urogenital infections: novel tools and new strategies point to bright future prospects.
    Hafner LM; Timms P
    Expert Rev Vaccines; 2018 Jan; 17(1):57-69. PubMed ID: 29264970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of Trachoma from Achham District, Nepal: A Cross-Sectional Study from the Nepal National Trachoma Program.
    Pant BP; Bhatta RC; Chaudhary JS; Awasthi S; Mishra S; Sharma S; Cuddapah PA; Gwyn SE; Stoller NE; Martin DL; Keenan JD; Lietman TM; Gaynor BD
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004462. PubMed ID: 26871898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Chlamydia trachomatis bacterial ghost vaccine to fight human blindness.
    Eko FO; Talin BA; Lubitz W
    Hum Vaccin; 2008; 4(3):176-83. PubMed ID: 18382139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B virus core antigen as a carrier for Chlamydia trachomatis MOMP multi-epitope peptide enhances protection against genital chlamydial infection.
    Jiang P; Du W; Xiong Y; Lv Y; Feng J; Zhu S; Xue X; Chen S; Zhang L
    Oncotarget; 2015 Dec; 6(41):43281-92. PubMed ID: 26657117
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Borges ÁH; Follmann F; Dietrich J
    Expert Rev Vaccines; 2022 Nov; 21(11):1555-1567. PubMed ID: 36004386
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    de la Maza LM; Darville TL; Pal S
    Expert Rev Vaccines; 2021 Apr; 20(4):421-435. PubMed ID: 33682583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community.
    West ES; Munoz B; Mkocha H; Holland MJ; Aguirre A; Solomon AW; Bailey R; Foster A; Mabey D; West SK
    Invest Ophthalmol Vis Sci; 2005 Jan; 46(1):83-7. PubMed ID: 15623758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future of human Chlamydia vaccine: potential of self-adjuvanting biodegradable nanoparticles as safe vaccine delivery vehicles.
    Sahu R; Verma R; Dixit S; Igietseme JU; Black CM; Duncan S; Singh SR; Dennis VA
    Expert Rev Vaccines; 2018 Mar; 17(3):217-227. PubMed ID: 29382248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.